NasdaqGS - Nasdaq Real Time Price USD

Replimune Group, Inc. (REPL)

17.61 +0.22 (+1.27%)

At close: October 30 at 4:00:00 PM EDT

17.60 -0.01 (-0.06%)

Overnight: 12:46:53 AM EST

Trade REPL on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for REPL

Previous Close 17.39
Open 17.49
Bid 12.94 x 200
Ask 21.56 x 200
Day's Range 16.64 - 18.27
52 Week Range 1.50 - 18.27
Volume 3,853,651
Avg. Volume 3,009,451
Market Cap (intraday) 1.669B
Beta (5Y Monthly) 0.94
PE Ratio (TTM) --
EPS (TTM) -2.79
Earnings Date Oct 28, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 23.33
Zacks Rating Bullish

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.

www.replimune.com

465

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

REPL

81.17%

S&P 500 (^GSPC)

10.73%

1-Year Return

REPL

71.80%

S&P 500 (^GSPC)

11.11%

3-Year Return

REPL

23.67%

S&P 500 (^GSPC)

81.91%

5-Year Return

REPL

40.33%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY27

Revenue --

Earnings -57.12M

Profit Margin 0.00%

FY26

FY27

-60M

-40M

-20M

0.0%

Analyst Price Targets

14.00 Low

23.33 Average

17.61 Current

31.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 10/29/2026

Analyst Leerink Partners

Rating Action Maintains

Rating Outperform

Price Action Raises

Price Target 19 -> 31

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-43.95%
Return on Equity (ttm)

-115.80%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-271.03M
Diluted EPS (ttm)

-2.79

Balance Sheet and Cash Flow

Total Cash (mrq)

307.83M
Total Debt/Equity (mrq)

62.11%
Levered Free Cash Flow (ttm)

-148.3M

SRRK Scholar Rock Holding Corporation

43.90 -0.63%

SNDX Syndax Pharmaceuticals, Inc.

13.65 -3.53%

STOK Stoke Therapeutics, Inc.

26.29 -0.23%

KURA Kura Oncology, Inc.

10.26 -2.84%

IDYA IDEAYA Biosciences, Inc.

31.96 -2.83%

U.S. markets open in 5h 20m

Replimune Group, Inc. (REPL)

Trading disclosure

53.66%

33.01%

585.21%

81.17%

71.80%

-40.33%

10.06%

Replimune Group, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch